UNSPSC 51151912: Thiocolchicoside

This classification denotes a colchicine analog and hysterosalpingography adjunct with the molecular formula C27H33NO10S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T1X8S697GT, chemically known as colchicoside, 10-thio- (8ci) but generally known as thiocolchicoside, which bears US NIH Compound Identifier 72067. European Medicines Agency schedules Thiocolchicoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10976MIG.

UNSPSC 51151912 Thiocolchicoside is a Commodity code designating a specific pharmaceutical agent, but the recent state and local opportunities posted under this code show little alignment with the nominal substance. Seminole County, Florida is soliciting Naloxone and Safe Drug Deactivation Systems through an IFB (Solicitation IFB60459723LAS, due Jul 26, 2023), and the Texas Health and Human Services Commission has issued an RFI (HHS0017013, posted Apr 3, 2026) exploring direct-to-manufacturer prescription programs — neither of which involves thiocolchicoside procurement. The mismatch suggests either tagging inconsistency in the source data or that this Commodity code sees minimal relevant activity in current state and local procurement. When opportunities do appear under this code, they typically involve pharmaceutical acquisition for health departments and state health agencies, though the recent record does not support a clear pattern of thiocolchicoside-specific demand.

The geographic activity reflected in these opportunities spans Florida and Texas, representing state-level health agencies and county public-health functions. Seminole County's naloxone and drug deactivation system procurement is budgeted at an unspecified fixed-fee level with annual volumes of 1,900 units of naloxone and 800 systems, delivered quarterly to the Seminole County Community Health Building; the contract carries a two-year initial term with a one-year renewal option and may be federally funded through FEMA. The Texas HHS Commission's RFI is a market-intelligence tool preceding formal procurement and does not indicate award values or timelines. Given the limited and tangential recent activity, this code warrants a watch status rather than active pursuit unless your firm has direct pharmaceutical-supply relationships with county health departments or state HHS agencies exploring new acquisition models.